UK becomes the first European country to license a GLP-1 weight-loss tablet

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved a daily semaglutide (Wegovy) tablet for weight loss and weight management on 11 June 2026, making it the first GLP-1 receptor agonist pill licensed for obesity in the UK ^[1]. The BMJ described it as the first GLP-1 pill approved by the MHRA for weight loss and weight management, noting the drug had until now been approved only in injectable form for that use ^[2].

The license covers adults with obesity, defined as a body mass index (BMI) of 30 or above, and adults who are overweight with a BMI between 27 and 30 who also have at least one weight-related health condition ^[1]. In both groups, the tablet is meant to be used alongside a reduced-calorie diet and increased physical activity ^[1]. The MHRA emphasized that, like all GLP-1 receptor agonists, it is prescription-only ^[1].

How the tablet is dosed and taken

The approved schedule starts at 1.5 mg once daily and steps up to 4 mg, 9 mg and 25 mg, with a minimum of one month at each dose level ^[1]. People already being treated privately with the 2.4 mg once-weekly semaglutide injection can be switched directly to the 25 mg tablet once daily, according to the MHRA ^[1].

Timing matters with this formulation. The MHRA said the tablet should be swallowed whole on an empty stomach after fasting for at least eight hours, with a sip of water, and that no food or drink should follow for at least 30 minutes ^[1]. Eating or drinking sooner than 30 minutes after the dose lowers how much of the drug the body absorbs ^[1].

Semaglutide mimics glucagon-like peptide-1, a hormone the body releases after eating, and acts on brain areas that regulate appetite, helping people feel fuller for longer and reducing hunger and food cravings ^[1]. The most common side effects listed by the regulator are gastrointestinal: nausea, diarrhea, constipation and vomiting ^[1]. The MHRA said it keeps the safety and effectiveness of semaglutide under close review and asked people who suspect a side effect to report it through its Yellow Card scheme ^[1].

"Having met the MHRA's rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management," said Julian Beach, the agency's executive director of healthcare quality and access ^[1].

Oral semaglutide is not new to the UK — it is already approved there for type 2 diabetes under the brand name Rybelsus ^[2]. What changed on 11 June is the addition of a weight-management indication for the tablet, granted to Novo Nordisk ^[1].

Why it matters for patients

Approval is not the same as access. The MHRA said plainly that the tablet is not currently available through the NHS and that decisions on NHS use will follow established processes, including an evaluation by the National Institute for Health and Care Excellence (NICE) ^[1]. The BMJ made the same point, saying the approval opens the door to more UK patients taking the oral version but that it must clear further steps first ^[2]. Reports that private providers would stock the tablet within weeks are not confirmed in the sources reviewed here, and no launch date or price appears in the MHRA announcement ^[1][2].

For US readers, this is a UK regulatory action and does not change what is available in American pharmacies. Neither source addresses US Food and Drug Administration status, pricing or coverage for an oral semaglutide weight-loss product, so that remains outside what these documents show ^[1][2].

Still, the details are informative for anyone weighing a pill versus an injection. The strict fasting-and-waiting rules and the month-by-month dose escalation give a sense of what daily oral GLP-1 treatment involves, and the direct switch option from a 2.4 mg weekly injection to a 25 mg daily tablet shows how regulators view the two forms as interchangeable at those doses ^[1].

What happens next

The MHRA said the Summary of Product Characteristics and Patient Information Leaflet would be published on its products website within seven days of the 11 June 2026 approval ^[1]. A NICE evaluation would determine any NHS use; no timeline for that review is given in these sources ^[1].